Biomerica, Inc. (BMRA) Fair Value 2026

BMRA · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-28, Biomerica, Inc. (BMRA) trades at $2.14, versus a $2.33 median fair value across its 2 active models — 8.9% above the current price. QOC: 5.7/10. Value Trap Risk: 35/100 (LOW). 2/13 models active.

Key Facts

Ticker
BMRA
Price
$2.14
Quality Score
5.7/10
Value Trap Risk
35/100
Models Active
2/13
Last Updated
Strength: Regime Cross-Sectional suggests +54.6% upside with 17% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is Biomerica, Inc. (BMRA) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Biomerica, Inc. (BMRA) appears fairly valued as of : the median of 2 independent fair value estimates is $2.33, within 8.9% of the current price of $2.14. Estimates range from $1.35 to $3.31. BMRA scores 5.7/10 on fundamental quality and 35/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. BMRA’s +8.9% gap is narrower than that market norm, and the Medical Devices sector median is -43.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Biomerica, Inc. Stock in 2026? →

What Fair Value Does Each Model Give BMRA?

2 Intrinsic Value Models vs. Current Price ($2.14)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $1.35 -36.9%
Relative · Low Conviction
 $3.31 +54.6%

All Models Active

All 2 models are displayed above.

What Is Biomerica, Inc. (BMRA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Biomerica, Inc. presents a highly debated valuation profile at its current price of $2.14. The median intrinsic value is estimated at $2.33 (+8.9% median upside), masking a wide model spread between the 1 bullish models and 1 bearish models. Model dispersion is worth noting: Regime Cross targets $3.31 (+54.6%), versus ML-RIV at $1.35 (-36.9%). This +91.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About BMRA?

2 of 13 models are currently active for BMRA. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for BMRA is $2.33 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does BMRA Rank in Medical Devices?

Among 159 Medical Devices stocks, BMRA ranks #104 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to biopharma enterprise businesses. For Biomerica, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is BMRA a Value Trap?

CirclFi's Value Trap algorithm assigns BMRA a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Biomerica, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Biomerica, Inc. scores 5.7 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +91.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BMRA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BMRA's 2 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Biomerica, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

TLSITriSalus Life Sciences, Inc.QOC 5.7SINTSintx Technologies, Inc.QOC 5.7VNRXVolitionRx LimitedQOC 5.7QTIQT Imaging Holdings, Inc.QOC 5.6CVCapsoVision, Inc.QOC 5.7NNOXNano-X Imaging Ltd.QOC 5.6NVNOenVVeno Medical CorporationQOC 4.2MDNCMedinotec Inc.QOC 8.2MYOMyomo, Inc.QOC 6.6IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: TLSI · SINT · VNRX · QTI · CV · NNOX · NVNO · MDNC · MYO · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to BMRA?

7 companies across all industries closest to BMRA’s Quality of Company score of 5.7/10.

FLWS1-800-FLOWERS.COM, Inc.QOC 5.7VISLVislink Technologies, Inc.QOC 5.7LIMENeutron Holdings, Inc.QOC 5.7WALDWaldencast plcQOC 5.7APCXAppTech Payments Corp.QOC 5.7GRRRGorilla Technology Group Inc.QOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FLWS · VISL · LIME · WALD · APCX · GRRR · NVDA

Where Does BMRA Sit in CirclFi's Medical Devices Rankings?

BMRA is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Biomerica, Inc.’s Valuation?

What is Biomerica, Inc.'s intrinsic value in 2026?

CirclFi puts Biomerica, Inc. (BMRA)'s intrinsic value at $2.33 — the median of 2 independent model estimates as of 2026-08-28, ranging from $1.35 to $3.31. The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BMRA overvalued or undervalued right now?

At $2.14, 1 of 2 active models suggest BMRA may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $2.33, within 8.9% of the current price of $2.14 — a consensus view that BMRA is fairly valued. The assessment depends on which methodology best fits Biomerica, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.7 mean for BMRA?

Biomerica, Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BMRA?

CirclFi analyzes BMRA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is BMRA a value trap in 2026?

Biomerica, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Biomerica, Inc. (BMRA) has a median fair value of $2.33 — within 8.9% of the current price of $2.14 — as of 2026-08-28.” Source: circlfi.com/stock/BMRA/ · Methodology
Primary sources for this BMRA valuation
  • Financial statements: Biomerica, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000073290) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BMRA as of ; valuations recomputed .